Breast care (Basel, Switzerland)最新文献

{"title":"Stereotactic Vacuum-Assisted Breast Biopsy in Ductal Carcinoma in situ: Residual Microcalcifications and Intraoperative Findings.","authors":"Benedict Krischer,&nbsp;Serafino Forte,&nbsp;Gad Singer,&nbsp;Rahel A Kubik-Huch,&nbsp;Cornelia Leo","doi":"10.1159/000502944","DOIUrl":"https://doi.org/10.1159/000502944","url":null,"abstract":"<p><strong>Purpose: </strong>The question of overtreatment of ductal carcinoma in situ (DCIS) was raised because a significant proportion of especially low-grade DCIS lesions never progress to invasive cancer. The rationale for the present study was to analyze the value of stereotactic vacuum-assisted biopsy (VAB) for complete removal of DCIS, focusing on the relationship between the absence of residual microcalcifications after stereotactic VAB and the histopathological diagnosis of the definitive surgical specimen.</p><p><strong>Patients and methods: </strong>Data of 58 consecutive patients diagnosed with DCIS by stereotactic VAB in a single breast center between 2012 and 2017 were analyzed. Patient records from the hospital information system were retrieved, and mammogram reports and images as well as histopathology reports were evaluated. The extent of microcalcifications before and after biopsy as well as the occurrence of DCIS in biopsy and definitive surgical specimens were analyzed and correlated.</p><p><strong>Results: </strong>There was no correlation between the absence of residual microcalcifications in the post-biopsy mammogram and the absence of residual DCIS in the final surgical specimen (<i>p</i> = 0.085). Upstaging to invasive cancer was recorded in 4 cases (13%) but occurred only in the group that had high-grade DCIS on biopsy. Low-grade DCIS was never upgraded to high-grade DCIS in the definitive specimen.</p><p><strong>Conclusions: </strong>The radiological absence of microcalcifications after stereotactic biopsy does not rule out residual DCIS in the final surgical specimen. Since upstaging to invasive cancer is seen in a substantial proportion of high-grade DCIS, the surgical excision of high-grade DCIS should remain the treatment of choice.</p>","PeriodicalId":520575,"journal":{"name":"Breast care (Basel, Switzerland)","volume":" ","pages":"386-391"},"PeriodicalIF":2.1,"publicationDate":"2020-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000502944","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38425732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of Conservative versus Surgical Treatment Protocols in Treating Idiopathic Granulomatous Mastitis: A Meta-Analysis.","authors":"Fei Zhou,&nbsp;Lu Liu,&nbsp;Liyuan Liu,&nbsp;Lixiang Yu,&nbsp;Fei Wang,&nbsp;Yujuan Xiang,&nbsp;Chao Zheng,&nbsp;Shuya Huang,&nbsp;Han Cai,&nbsp;Zhigang Yu","doi":"10.1159/000503602","DOIUrl":"https://doi.org/10.1159/000503602","url":null,"abstract":"<p><strong>Background: </strong>Idiopathic granulomatous mastitis (IGM) is a rare, benign breast disease without any definitive therapeutic strategy. It is controversial whether to use conservative or surgical treatment of IGM and high-level evidence-based medicine data are lacking. The purpose of this study was to systemically evaluate the clinical effectiveness of the conservative versus surgical treatment for IGM.</p><p><strong>Methods: </strong>In this meta-analysis, we searched PubMed, EMbase, ScienceDirect, and Web of Science for comparative studies about the conservative versus surgical treatment of IGM. Two researchers independently identified reports and extracted data. We used Stata 11 for data analysis. A meta-analysis was performed to investigate the differences in the recurrence rate of conservative and surgical treatment using a random effects model.</p><p><strong>Results: </strong>A total of 10 studies involving 1,101 patients were included. The results demonstrated that there was no significant difference in the recurrence rate among patients who were treated by nonsurgical therapy and surgical treatment. No publication bias was detected.</p><p><strong>Conclusion: </strong>This meta-analysis demonstrates that both the conservative and surgical treatment approaches have appropriate efficacy in IGM treatment and relapse. Further randomized controlled trials with longer follow-up periods are required to confirm the advantages of each approach.</p>","PeriodicalId":520575,"journal":{"name":"Breast care (Basel, Switzerland)","volume":" ","pages":"415-420"},"PeriodicalIF":2.1,"publicationDate":"2020-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000503602","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38425736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-Lasting Response after Pembrolizumab in a Patient with Metastatic Triple-Negative Breast Cancer.","authors":"Paloma Peinado,&nbsp;Carmen Ramírez,&nbsp;José Angel García-Sáenz,&nbsp;Alejandro Pascual,&nbsp;Jesús Fuentes-Antrás,&nbsp;Natalia Vidal,&nbsp;Mónica Antoñanzas,&nbsp;Fernando Moreno","doi":"10.1159/000503849","DOIUrl":"https://doi.org/10.1159/000503849","url":null,"abstract":"<p><strong>Introduction: </strong>Breast cancer is the first cause of cancer death in women. The triple-negative subtype is associated with aggressive behavior and poor prognosis. Chemotherapy is the main therapeutic option available for these patients, but it is usually associated with short overall survival.</p><p><strong>Case presentation: </strong>We report the case of a patient diagnosed with metastatic triple-negative breast cancer with an impressive long-lasting tumor response and long-term survival after pembrolizumab monotherapy.</p><p><strong>Conclusion: </strong>Immunotherapy is emerging as a promising treatment for some breast cancer patients. Nevertheless, monotherapy studies have shown a very limited activity. Nowadays, there is no good predictor biomarker. Further investigations are needed to identify the subgroup of patients who can benefit from checkpoint inhibitor treatment.</p>","PeriodicalId":520575,"journal":{"name":"Breast care (Basel, Switzerland)","volume":" ","pages":"428-432"},"PeriodicalIF":2.1,"publicationDate":"2020-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000503849","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38425738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endocrine Therapy in Early Breast Cancer.","authors":"Katja Krauss,&nbsp;Elmar Stickeler","doi":"10.1159/000509362","DOIUrl":"https://doi.org/10.1159/000509362","url":null,"abstract":"<p><strong>Background: </strong>Endocrine therapy with a standard duration of 5 years is well known as an effective treatment for endocrine-sensitive breast cancer.</p><p><strong>Summary: </strong>In the adjuvant setting this treatment reduces the 15-year mortality rates by about 30 and 40% with tamoxifen and aromatase inhibitor, respectively. The well-known long-term recurrence risk of luminal cancers led to multiple trials examining the benefit of extended endocrine treatment for up to 15 years. Additional benefit with extended therapy was seen for patients with high recurrence risk. Also, additional ovarian suppression for premenopausal women exhibited a significant benefit for patients at higher risk.</p><p><strong>Key messages: </strong>The data of the last years will be summarized and discussed, also considering the side effects of the different treatment options.</p>","PeriodicalId":520575,"journal":{"name":"Breast care (Basel, Switzerland)","volume":" ","pages":"337-346"},"PeriodicalIF":2.1,"publicationDate":"2020-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000509362","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38425259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Commentary on Nguyen et al. \"Living with Male Breast Cancer: A Qualitative Study of Men's Experiences and Care Needs\".","authors":"Nicole Ernstmann,&nbsp;Christoph Kowalski","doi":"10.1159/000503778","DOIUrl":"https://doi.org/10.1159/000503778","url":null,"abstract":"Dear Editor, In their recent article, Nguyen et al. [1] presented research on experiences and needs of male breast cancer patients in Germany. Breast cancer in men is a rare condition, and studies exploring the needs of male breast cancer patients are still needed. The authors conducted semi-structured interviews with n = 18 patients and performed qualitative content analysis. We congratulate the authors to contributing to a better understanding of the specific needs of these men and their caregivers. Describing the current state of research, the authors refer to the health services’ research gap concerning male breast cancer. Some of these gaps have been addressed in prior work conducted by a multidisciplinary research team, including the authors of this letter, within the N-MALE study (“Male breast cancer: patients’ needs in prevention, diagnosis, treatment, rehabilitation, and follow-up care”) that was funded by the German Cancer Aid between 2016 and 2018. Results of this study have been published in this Breast Care [2] as well as others [3–5]. These results are based on a study sample of n = 100 male breast cancer patients across Germany. We used a mixed-methods approach by triangulating qualitative interview data from n = 27 patients and standardized survey data from 100 patients. In addition, we incorporated the perspective of health professionals involved in male breast cancer care and conducted semi-structured interviews with n = 23 participants and two focus group discussions with n = 16 participants. The central findings of both Nguyen et al. [1] as well as the NMALE study regarding the patient perspective are in accordance: both studies report some experiences of stigmatization and of shortcomings including barriers in access to gynecological outpatient care and unclear responsibilities. This replication of findings validates the results of both studies. Besides the qualitative exploration of the patients’ perspectives, our survey results can help quantify the occurrence of stigmatization or barriers to receiving care. Nguyen et al. [1] describe “a lack of awareness and experience of treating males among health professionals” as a central experience male breast cancer patients make. Our data analyzing the healthcare provider interviews show a similar pattern: we found insecurities in terms of treatment recommendations or responsibilities, and a lack of interdisciplinary cooperation, especially in follow-up care [5]. Following the N-MALE study’s initial results, two of the findings that were also addressed by Nguyen et al. [1] were investigated in more detail or processed; one considers the challenges of reimbursement of male breast cancer care in gynecology practices [6]. Based on a representative national survey of the associations of statutory health insurance physicians in all federal states of Germany, we found divergent practices in the states [7]. In short, office-based gynecologists get their services reimbursed depending on th","PeriodicalId":520575,"journal":{"name":"Breast care (Basel, Switzerland)","volume":" ","pages":"437-438"},"PeriodicalIF":2.1,"publicationDate":"2020-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000503778","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38425740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence and Predictors for Nonuse of Complementary Medicine among Breast and Gynecological Cancer Patients.","authors":"Daniela Paepke,&nbsp;Clea Wiedeck,&nbsp;Alexander Hapfelmeier,&nbsp;Kristina Karmazin,&nbsp;Marion Kiechle,&nbsp;Christine Brambs","doi":"10.1159/000502942","DOIUrl":"https://doi.org/10.1159/000502942","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Complementary and alternative medicine (CAM) use is common among cancer patients. Data indicated that CAM use correlates with younger age, higher education levels, higher income, and less physician consultations. However, non-CAM use and predictors for non-CAM use are less clear among breast and gynecological cancer patients.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objectives: &lt;/strong&gt;The purpose of this study was to determine the prevalence of non-CAM use and to investigate factors that might influence non-CAM use.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;The survey was conducted in breast cancer patients from January to May 2013 and in gynecological cancer patients from January to May 2014 with 2 pseudoanonymous questionnaires: one for CAM users (109 questions) and one for non-CAM users (85 questions). The survey was conducted via a telephone interview with 333 patients. Eligible participants were women with breast cancer (&lt;i&gt;n&lt;/i&gt; = 285) and gynecological cancer (&lt;i&gt;n&lt;/i&gt; = 291) who had undergone surgery at the Department of Gynecology and Obstetrics at the Technical University Munich, Germany, in the years 2012 (breast cancer) and 2011-2013 (gynecological cancer). Descriptive statistics were generated to determine patterns of non-CAM use. Univariable analysis was used to detect patient characteristics associated with noninterest in the different CAM therapies.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;A total of 333 of 576 patients participated in the survey (58%). Fifty-eight percent (&lt;i&gt;n&lt;/i&gt; = 192/333) were diagnosed with breast cancer and 42% (&lt;i&gt;n&lt;/i&gt; = 141/333) with gynecological cancer. The overall prevalence of non-CAM use was 42% (&lt;i&gt;n&lt;/i&gt; = 139/333). Eighty-one percent (&lt;i&gt;n&lt;/i&gt; = 112/139) of the non-CAM users stated to have received no recommendation for CAM use, although 53% (&lt;i&gt;n&lt;/i&gt; = 73/139) would have liked to receive information from their physician. As reasons for the nonuse of CAM therapies, 76% (&lt;i&gt;n&lt;/i&gt; = 106/139) nonusers declared that they did not believe CAM use was necessary since the conventional therapy was considered sufficient, 44% (&lt;i&gt;n&lt;/i&gt; = 61/139) reported a lack of information, 31% (&lt;i&gt;n&lt;/i&gt; = 43/139) a fear of fraud, and 22% (&lt;i&gt;n&lt;/i&gt; = 31/139) a fear of interactions and side effects of CAM. Sixty-eight percent (&lt;i&gt;n&lt;/i&gt; = 95/139) of the patients stated that they would resort to CAM if the disease progressed while only 27% (&lt;i&gt;n&lt;/i&gt; = 37/139) would still not use any CAM with progression of disease. Five percent (7/139) did not give any information regarding possible future CAM use with disease progression. Seventy-three percent (&lt;i&gt;n&lt;/i&gt; = 102/139) would both welcome more physicians with qualifications in complementary medicine and supported an integration of CAM into our health care system. Furthermore, statistically significant correlations between patients' sociodemographic characteristics and their nonuse of complementary therapies were identified.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;Our data demonstrate a high over","PeriodicalId":520575,"journal":{"name":"Breast care (Basel, Switzerland)","volume":" ","pages":"380-385"},"PeriodicalIF":2.1,"publicationDate":"2020-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000502942","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38425263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Virtual Science in Senology: Let Us Not Throw out the Baby with the Bathwater.","authors":"Nadia Harbeck,&nbsp;Christoph Thomssen,&nbsp;Michael Gnant","doi":"10.1159/000510067","DOIUrl":"https://doi.org/10.1159/000510067","url":null,"abstract":"","PeriodicalId":520575,"journal":{"name":"Breast care (Basel, Switzerland)","volume":" ","pages":"323-324"},"PeriodicalIF":2.1,"publicationDate":"2020-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000510067","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38425256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Are There Disparities in Surgical Treatment for Breast Cancer Patients with Prior Physical Disability A Path Analysis.","authors":"Lena Ansmann,&nbsp;Alfred Schabmann,&nbsp;Sophie Elisabeth Gross,&nbsp;Anke Gross-Kunkel,&nbsp;Ute-Susann Albert,&nbsp;Igor Osipov","doi":"10.1159/000503777","DOIUrl":"https://doi.org/10.1159/000503777","url":null,"abstract":"<p><strong>Introduction: </strong>Cancer care for patients with prior physical disability has hardly been researched in clinical research, health services research, or special education. This article aims to compare the severity of disease and the surgical treatment of diagnosed breast cancer patients with and without prior physical disability.</p><p><strong>Methods: </strong>A total of 4,194 patients with primary breast cancer who underwent surgery in a breast cancer center in North Rhine-Westphalia, Germany, participated in an annual postoperative postal survey, which was complemented by clinical data. Latent class analysis and logit path models were applied to study (1) differences in terms of UICC staging and local cancer treatment between patients with and without prior physical disability and (2) respective differences by disability severity.</p><p><strong>Results: </strong>Patients with physical disability (<i>n</i> = 780; 18.7%) had a higher chance of receiving mastectomy compared to breast-conserving therapy, even after controlling for socioeconomic status and UICC staging. Disability severity is directly and indirectly associated with receiving a mastectomy.</p><p><strong>Conclusion: </strong>In light of the research gap on disability and cancer, this work indicates disparities in care for breast cancer patients with prior physical disability. Inequalities might be attributable to (1) unequal access to care, (2) individual preferences and difficulties, or (3) medical difficulties.</p>","PeriodicalId":520575,"journal":{"name":"Breast care (Basel, Switzerland)","volume":" ","pages":"400-407"},"PeriodicalIF":2.1,"publicationDate":"2020-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000503777","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38425734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Breast Reconstruction with Perforator Flaps in Poland Syndrome: Report of a Two-Stage Strategy and Literature Review.","authors":"Boyang Xu,&nbsp;Tong Liu,&nbsp;Chunjun Liu","doi":"10.1159/000503848","DOIUrl":"https://doi.org/10.1159/000503848","url":null,"abstract":"<p><strong>Background: </strong>Poland syndrome is a congenital deformity presenting unilateral hypoplasia of the breast, pectoralis muscle, and ipsilateral skeletal anomalies. In complex female cases, the significant amount of soft tissue needed for reconstruction continues to be a surgical challenge. Perforator flaps offer alternative methods with sufficient tissue volume, minimal donor site morbidity, and natural cosmetic outcome; however, their role in Poland syndrome breast reconstruction is seldom discussed. This study aims to present a new 2-stage strategy for esthetic restoration of the Poland syndrome chest anomaly that achieves breast symmetry while maintaining a scarless appearance.</p><p><strong>Case presentation: </strong>A 38-year-old female presented with Poland syndrome on the right side, and amastia, athelia, and absence of pectoralis major muscle were observed. We present an innovative 2-stage approach consisting of tissue expansion and, successively, a deep inferior epigastric perforator flap transfer. A pleasing breast appearance had been achieved at 6 months of follow-up. A literature review regarding the use of free perforator flaps in Poland syndrome was conducted to demonstrate the applicability of this method. Seven articles described a total of 15 cases using free perforator flaps met the inclusion criteria and were summarized. A satisfactory correction was reported in all the cases.</p><p><strong>Conclusion: </strong>Perforator flaps provide reliable alternatives for Poland syndrome breast and chest-wall reconstruction. Proper patient selection and thorough assessment are vital to the success of the surgery.</p>","PeriodicalId":520575,"journal":{"name":"Breast care (Basel, Switzerland)","volume":" ","pages":"421-427"},"PeriodicalIF":2.1,"publicationDate":"2020-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000503848","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38425737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High Incidence of Axillary Web Syndrome among Breast Cancer Survivors after Breast Reconstruction.","authors":"Hsiu-Chen Huang,&nbsp;Hui-Hua Liu,&nbsp;Li-Yun Yin,&nbsp;Chao-Hui Weng,&nbsp;Chien-Liang Fang,&nbsp;Cheng-San Yang","doi":"10.1159/000501928","DOIUrl":"https://doi.org/10.1159/000501928","url":null,"abstract":"<p><strong>Objective: </strong>The aim of this study was to identify if breast reconstruction is a surgical risk factor for axillary web syndrome (AWS) in breast cancer (BC) patients.</p><p><strong>Methods: </strong>The data of 207 patients who have been diagnosed with unilateral BC and who had mastectomy and lymph node dissection were retrospectively reviewed. Information of their clinical and pathological data, whether they had immediate -reconstruction and intraoperative radiotherapy, surgical methods, and postoperative complications during the 3 months after their surgery (AWS, lymphedema, seroma, and myofascial adhesion) were collected, and the incidence of AWS was compared between different surgical methods.</p><p><strong>Results: </strong>The overall incidence of AWS was 48.8% in 207 patients. Of the 22 patients who received reconstruction, 19 developed AWS, yielding an incidence of 86%. Multivariate logistic regression modeling showed that patients who underwent reconstruction had a significantly higher incidence of AWS (odds ratio, 4.74), as did patients with postoperative complication of myofascial adhesion (odds ratio, 7.07).</p><p><strong>Conclusions: </strong>BC survivors after breast reconstruction are susceptible to AWS, and there is a significant association between myofascial adhesion and AWS. Our results can stimulate further investigation and provide an evidence base for the development of educational guidance for patients who plan to undergo breast reconstruction.</p>","PeriodicalId":520575,"journal":{"name":"Breast care (Basel, Switzerland)","volume":" ","pages":"366-371"},"PeriodicalIF":2.1,"publicationDate":"2020-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000501928","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38425261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}